A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, September 9th-12th , hybrid congress
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.